Welcome to our dedicated page for Oramed Pharmaceuticals SEC filings (Ticker: ORMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oramed Pharmaceuticals Inc. (ORMP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Oramed’s filings reflect its status as a clinical-stage pharmaceutical company and platform technology pioneer in oral delivery solutions for drugs currently delivered via injection, and they document both its operating activities and its capital markets transactions.
Current and periodic reports such as Form 8-K detail material events, including option and warrant agreements, restructuring of notes, joint venture terminations, adoption of a Rights Agreement, and dividend declarations. For example, Oramed has filed 8-K reports describing its Option Agreement for the repurchase of Scilex warrants, restructuring of Scilex debt into convertible notes and warrants, the termination of a joint venture agreement with Hefei Tianhui Biotech Co., Ltd., and the adoption of a Rights Agreement that includes a dividend of common stock purchase rights.
Financial reporting is captured in quarterly and annual filings (Forms 10-Q and 10-K), which include Oramed’s financial statements, management’s discussion and analysis, and notes regarding its oral insulin program, POD™ technology development, and diversified investment portfolio. These documents provide context on how investments in entities such as Scilex Holding Company and Alpha Tau Medical Ltd. are reflected in the company’s financial condition and results of operations.
Filings also cover corporate governance and equity compensation, such as amendments to the company’s stock incentive plan and voting results from annual meetings of stockholders, as well as details on Oramed’s common stock registration on The Nasdaq Capital Market and the Tel Aviv Stock Exchange.
On Stock Titan, AI-powered tools summarize key points from Oramed’s 10-K, 10-Q, and 8-K filings, helping users quickly understand complex disclosures, track changes in financing arrangements, and review material agreements. Investors can also monitor updates related to rights plans and other actions that may affect the rights of security holders.
Oramed Pharmaceuticals Inc. completed the sale of its wholly owned subsidiary Oratech Pharma, Inc. to Lifeward Ltd. and closed a related financing on Lifeward securities. In exchange for Oratech, Oramed received 1,250,363 Lifeward ordinary shares, 1,006,113 pre-funded warrants at an exercise price of $0.0001 per share, and warrants to purchase up to 1,296,296 Lifeward shares at $5.40 per share. Oramed will also receive 4% revenue-sharing payments on Lifeward’s ReWalk Personal Exoskeleton products, subject to a 10-year limit, a maximum aggregate amount, or Lifeward reaching a $200 million market capitalization. Separately, Oramed purchased $9,000,000 in senior secured convertible notes from Lifeward, initially convertible at $5.40 per share, plus additional warrants to buy up to 1,666,666 Lifeward shares at $5.40 per share.
ORAMED PHARMACEUTICALS INC. President and CEO Nadav Kidron reported a routine tax-related share disposition. On March 30, 2026, 44,818 shares of common stock were used to satisfy tax withholding obligations from the vesting of Restricted Stock Units at $3.31 per share. These shares were not sold in the open market but withheld to cover taxes. Following this, Kidron directly holds 3,422,243 common shares and indirectly holds 126,000 common shares through a wholly-owned corporation.
ORAMED PHARMACEUTICALS INC. Chief Scientific Officer Miriam Kidron reported a tax-related share disposition tied to equity compensation. A total of 435,084 shares of common stock were used to satisfy tax withholding obligations from the vesting and settlement of Restricted Stock Units. These shares were valued at $3.31 per share, based on the closing price immediately before the vesting date. Following this tax-withholding disposition, Kidron directly holds 1,133,138 shares of Oramed common stock.
Oramed Pharmaceuticals Inc. files its annual report outlining a major strategic evolution. The company remains focused on oral delivery of proteins, including an oral insulin capsule, and plans a 60‑patient U.S. clinical trial in 2026 targeting high‑responder diabetes subpopulations via OraTech.
Oramed terminated its joint venture with HTIT, then transferred its POD oral delivery platform and OraTech equity to Lifeward in exchange for up to 49.99% fully diluted equity, warrants and revenue sharing on ReWalk Personal Exoskeleton sales, plus senior secured convertible notes. It also deploys significant capital into healthcare equities, royalties, and loans, including sizable stakes in Alpha Tau, Nano Dimension, Scilex‑linked notes and royalties, a new Corner Ally Ventures fund commitment, and several Israeli real estate and project‑finance loans, while warning that these concentrated investments and counterparties’ performance pose material risks.
ORAMED PHARMACEUTICALS INC. reported that Chief Scientific Officer Miriam Kidron received a grant of 119,558 restricted stock units (RSUs) of common stock. These RSUs will vest in eight equal quarterly installments beginning on April 1, 2026, providing staged equity-based compensation over two years.
Each RSU represents the right to receive one share of common stock with a par value of $0.012 per share. Following this award, Kidron’s reported direct holdings increased to 1,568,222 shares of common stock, indicating this is a sizable but compensation-related, non-cash acquisition rather than an open-market purchase.
KIDRON NADAV reported acquisition or exercise transactions in this Form 4 filing.
Oramed Pharmaceuticals reported that President and CEO Nadav Kidron received a grant of 167,005 Restricted Stock Units (RSUs) of common stock at no cash cost. The award increases his direct holdings to 3,422,243 shares after the transaction.
The RSUs will vest in eight equal quarterly installments beginning April 1, 2026, aligning a portion of the CEO’s compensation with the company’s long-term performance. Each RSU represents the right to receive one share of Oramed common stock as it vests.
Hexter Joshua reported acquisition or exercise transactions in this Form 4 filing.
ORAMED PHARMACEUTICALS INC. reported that its COO & CBO, Joshua Hexter, received a grant of 95,889 shares of Common Stock in the form of Restricted Stock Units. These RSUs will vest in eight equal quarterly installments beginning on April 1, 2026, with each RSU delivering one share upon vesting. Following this award, Hexter directly holds a total of 1,160,384 shares of the company’s common stock, reflecting a compensation-related equity grant rather than an open-market purchase.
Oramed Pharmaceuticals Chief Financial Officer Avraham Gabay received an equity grant of 95,889 Restricted Stock Units (RSUs). The RSUs vest in eight equal quarterly installments beginning on April 1, 2026, encouraging longer-term retention. Each RSU converts into one share of common stock when it vests, bringing his direct holdings to 745,145 shares after the award.
ORAMED PHARMACEUTICALS INC. President and CEO Nadav Kidron reported a bona fide charitable gift of 100,000 shares of Common Stock on March 12, 2026. The filing states this was a charitable donation, not a market transaction, and no value was received for the shares.
Following the donation, Kidron directly holds 3,255,238 shares of Oramed common stock. The footnote further explains that he is not affiliated with, and has no control over, the charitable donee, underscoring that this is a non-economic transfer rather than a sale in the open market.
Oramed Pharmaceuticals Inc. entered into a new warrant agreement with Scilex Holding Company on February 19, 2026. In return for previously deferring an amortization payment on Scilex’s senior secured convertible Tranche B Notes, Oramed received a February 2026 warrant to purchase 100,000 shares of Scilex common stock at an initial exercise price of $20.00 per share.
The warrant is immediately exercisable and expires on December 13, 2029. Its exercise price is adjustable for stock splits and certain future offerings, but not below a floor price of $8.22. The warrant includes a beneficial ownership cap of 4.99%, which Oramed may raise up to 9.99% with 61 days’ notice. It also contains protections in change-of-control and other fundamental transactions, including a right for Oramed to require cash repurchase of the unexercised portion at its Black Scholes value.